Roche to pay Simcere $75 million upfront for blood cancer drug rights
Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, Simcere said Tuesday.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, Simcere said Tuesday.